Somatic or germline mutations in TP53 gene that compromise its function occur in around 50% of all human cancers (IARC TP53 mutation database, version R14, November 2009 is the latest, [9]), and even those tumors that retain wild-type p53 frequently show defects in the pathways leading to its functional inactivation [10], such as amplification of MDM2 [11]. This evidence concerns the gene TP53 and cancer.